FCH
ELDN icon

Freestone Capital Holdings’s Eledon Pharmaceuticals ELDN Stock Holding History

Freestone Capital Holdings’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,366
Closed -$74.2K – 551
2025
Q2 		$74.2K Buy
+27,366
New +$82.1K ﹤0.01% 444

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Freestone Capital Holdings's ELDN Position: Q3 2025 in Review

Freestone Capital Holdings sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 27,366 shares — an estimated $74.2K sold.

Freestone Capital Holdings first reported a position in ELDN in Q2 2025 and held it in 1 quarter. The position peaked at $74.2K in Q2 2025. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Freestone Capital Holdings reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Freestone Capital Holdings sold 27,366 Eledon Pharmaceuticals shares in Q3 2025, an estimated $74.2K.
  • Freestone Capital Holdings first reported a position in Eledon Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Freestone Capital Holdings's Eledon Pharmaceuticals position peaked at $74.2K in Q2 2025.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Freestone Capital Holdings's 13F filing for Q3 2025, filed 12 Nov 2025.